Literature DB >> 28319078

Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?

N El-Jurdi1, M Ueda2, L Jia3, H Lazarus1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28319078     DOI： 10.1038/bmt.2017.20

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma.

Authors:  W R Drobyski; P Hari; C Keever-Taylor; R Komorowski; W Grossman
Journal:  Bone Marrow Transplant       Date:  2008-09-01       Impact factor: 5.483

2.  Autologous GVHD?

Authors:  F Otegbeye; R P Gale; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

3.  Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.

Authors:  A M Yeager; G B Vogelsang; R J Jones; E R Farmer; V Altomonte; A D Hess; G W Santos
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

Review 4.  Cytolytic pathways in haematopoietic stem-cell transplantation.

Authors:  Marcel R M van den Brink; Steven J Burakoff
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

5.  Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.

Authors:  S Giralt; D Weber; M Colome; M Dimopoulos; R Mehra; K Van Besien; J Gajewski; B Andersson; I Khouri; D Przepiorka; B von Wolff; K Delasalle; M Korbling; D Seong; R Alexanian; R Champlin
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.

Authors:  Leona Holmberg; Kaoru Kikuchi; Ted A Gooley; Kristina M Adams; David M Hockenbery; Mary E D Flowers; H Gary Schoch; William Bensinger; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

7.  Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation.

Authors:  Kristina M Adams; Leona A Holmberg; Wendy Leisenring; Alexander Fefer; Katherine A Guthrie; Tracy S Tylee; George B McDonald; William I Bensinger; J Lee Nelson
Journal:  Blood       Date:  2004-04-29       Impact factor: 22.113

8.  Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation.

Authors:  A F Hood; G B Vogelsang; L P Black; E R Farmer; G W Santos
Journal:  Arch Dermatol       Date:  1987-06

Review 9.  Autologous graft-vs-host disease: mechanisms and potential therapeutic effect.

Authors:  A D Hess; R C Jones; G W Santos
Journal:  Bone Marrow Transplant       Date:  1993       Impact factor: 5.483

10.  The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

Authors:  Christine Galustian; Brendan Meyer; Marie-Christine Labarthe; Keith Dredge; Deborah Klaschka; Jake Henry; Stephen Todryk; Roger Chen; George Muller; David Stirling; Peter Schafer; J Blake Bartlett; Angus G Dalgleish
Journal:  Cancer Immunol Immunother       Date:  2008-11-14       Impact factor: 6.968
View more
  2 in total

1.  Graft-versus-host disease in a child with neuroblastoma after autologous stem cell transplantation.

Authors:  Yöntem Yaman; Gökhan Baysoy; Emre Keleşoğlu; Kürşat Özdilli; Aslı Çakır; Dildar Bahar Genç; Murat Elli; Sema Anak
Journal:  Contemp Oncol (Pozn)       Date:  2019-03-25

2.  Failures in thymus medulla regeneration during immune recovery cause tolerance loss and prime recipients for auto-GVHD.

Authors:  Abdullah S Alawam; Emilie J Cosway; Kieran D James; Beth Lucas; Andrea Bacon; Sonia M Parnell; Andrea J White; William E Jenkinson; Graham Anderson
Journal:  J Exp Med       Date:  2021-12-15       Impact factor: 14.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.